OpinionDrugs to Target Lp(a): What’s ComingAuthor:Stephen J. Nicholls, MBBS, PhDPublish date: December 18, 2024Hopefully in the not-too-distant future, we’ll have specific therapies that really enable for us to address Lp(a) quite definitively.Read More
ArticleResults of the GLAGOV trialAuthor:Stephen J. Nicholls, MBBS, PhDPublish date: December 1, 2017Compared with statins alone, treatment with statins plus the PCSK9 inhibitor evolocumab lowered LDL-C more, produced greater atheroma regression, a...Read More
ArticleNiacin's effect on cardiovascular risk: Have we finally learned our lesson?Author:Stephen J. Nicholls, MBBS, PhDPublish date: May 1, 2014For now, the renaissance of niacin as a means of lowering cardiovascular risk is only wishful thinking.Read More
ArticleIs niacin ineffective? Or did AIM-HIGH miss its target?Author:Stephen J. Nicholls, MBBS, PhDPublish date: January 1, 2012A trial has thrown the use of niacin as a lipid-modifying therapy into question. But the results can be interpreted in several ways.Read More
ArticleExposing the complexity of HDLAuthor:Stephen J. Nicholls, MBBS, PhDPublish date: October 1, 2007HDL is a heterogeneous population of particles, and we should not be surprised if these particles differ in their effect on the arterial wall.Read More
ArticleCoronary atherosclerosis can regress with very intensive statin therapyAuthor:Stephen J. Nicholls, MBBS, PhDPublish date: October 1, 2006The optimal strategy for lipid-lowering in patients with coronary artery disease may be to aim for the lowest low-density lipoprotein cholesterol l...Read More
